Tourmaline Bio (TRML)
NASDAQ:TRML
US Market

Tourmaline Bio (TRML) Financial Statements

285 Followers

Tourmaline Bio Financial Overview

Tourmaline Bio's market cap is currently ―. The company's EPS TTM is $-6.495; its P/E ratio is -2.30; and it has a dividend yield of 101.39%. Tourmaline Bio is scheduled to report earnings on May 13, 2024, and the estimated EPS forecast is $-0.67. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -17.52M$ -6.32M$ -6.92M$ -14.65M$ -23.66M
EBITDA$ -17.51M$ -6.32M$ -7.90M$ -15.76M$ -24.30M
Net Income Common Stockholders$ -13.31M$ 2.13M$ -13.93M$ -14.74M$ -44.57M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 293.06M$ 202.95M$ 147.02M$ 152.25M$ 165.81M
Total Assets$ 359.17M$ 210.29M$ 151.06M$ 159.12M$ 172.61M
Total Debt$ 376.00K$ 415.00K$ 634.00K$ 1.03M$ 1.27M
Net Debt$ -292.68M$ -202.54M$ -146.39M$ -151.23M$ -164.54M
Total Liabilities$ 5.03M$ 5.25M$ 8.19M$ 10.69M$ 10.88M
Stockholders Equity$ 354.14M$ 205.04M$ 142.87M$ 148.43M$ 161.73M
Cash Flow-
Free Cash Flow$ -14.92M$ 11.51M$ -6.87M$ -14.90M$ -17.22M
Operating Cash Flow$ -14.92M$ 11.02M$ -7.52M$ -14.68M$ -16.90M
Investing Cash Flow$ -188.87M$ -88.42M$ 55.93M$ 8.92M$ 27.41M
Financing Cash Flow$ 161.35M$ 156.46M$ 74.00K$ 137.00K$ 46.00K
Currency in USD

Tourmaline Bio Earnings and Revenue History

Tourmaline Bio Debt to Assets

Tourmaline Bio Cash Flow

Tourmaline Bio Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis